Patents by Inventor Malcolm Carter

Malcolm Carter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10287578
    Abstract: The present invention relates to DNAzymes (also known as deoxyribozymes, DNA enzymes, catalytic DNA, or DZ), which are conjugated to nanoparticles (NP) to facilitate the detection of nucleic acids. One aspect of the invention relates to compounds comprising DNAzymes conjugated to nanoparticles (DZ-NP), such as metallic or gold nanoparticles, and methods for their synthesis. Another aspect of the invention relates to methods of using the conjugated compounds to detect nucleic acids, such as genomic material or transcripts of infectious agents, such as viruses, exemplified by applications demonstrating visual detection of Flavivirus RNA molecules, such as dengue virus, or Alphavirus RNA molecules, such as chikungunya virus, in short time periods, using compositions comprising stable components.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: May 14, 2019
    Assignee: The University of Notre Dame
    Inventors: James Carter, Malcolm J. Fraser, Jr.
  • Patent number: 8853204
    Abstract: A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: October 7, 2014
    Assignee: Arrow Therapeutics Limited
    Inventors: Kenneth Powell, Richard Kelsey, Malcolm Carter, Dagmar Alber, Lara Wilson, Elisa Henderson, Phil Chambers, Debra Taylor, Stan Tyms, Verity Dowdell
  • Patent number: 8119630
    Abstract: Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV Formula (I) Wherein: —R1 represents C1-6 alkyl, aryl or heteroaryl; —R2 represents hydrogen or C1-6 alkyl; -each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, —CO2R?, CONR?R?, —NH—CO—R?, —S(O)R?, —S(O)2R?, —NH—S(O)2R?, —S(O)NR?R? or —S(O)2NR?R? wherein each R? and R? is the same or different and represents hydrogen or C1-6 alkyl; -n is from 0 to 3; R4 represents hydrogen or C1-6 alkyl; —R6 represents C1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-C(O)—C(O)—, heteroaryl-C(O)—C(O)—, carbocyclyl-C(O)—C(O)—, heterocyclyl-C(O)—C(O)— or, —XR6; —X represents —CO—, —S(O)— or —S(0)2—; and —R6 represents C1-6 alkyl, hydroxy, C1-6 alk
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: February 21, 2012
    Assignee: Arrow Therapeutics Limited
    Inventors: Malcolm Carter, Elisa Henderson, Richard Kelsey, Lara Wilson, Phil Chambers, Debra Taylor, Stan Tyms
  • Publication number: 20100015063
    Abstract: Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV Formula (I) Wherein: —R1 represents C1-6 alkyl, aryl or heteroaryl; —R2 represents hydrogen or C1-6 alkyl; -each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, —CO2R?, CONR?R?, —NH—CO—R?, —S(O)R?, —S(O)2R?, —NH—S(O)2R?, —S(O)NR?R? or —S(O)2NR?R? wherein each R? and R? is the same or different and represents hydrogen or C1-6 alkyl; -n is from 0 to 3; R4 represents hydrogen or C1-6 alkyl; —R6 represents C1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-C(O)—C(O)—, heteroaryl-C(O)—C(O)—, carbocyclyl-C(O)—C(O)—, heterocyclyl-C(O)—C(O)— or, —XR6; —X represents —CO—, —S(O)— or —S(0)2—; and —R6 represents C1-6 alkyl, hydroxy, C1-6 alk
    Type: Application
    Filed: June 2, 2009
    Publication date: January 21, 2010
    Applicant: Arrow Therapeutics Limited
    Inventors: Malcolm Carter, Elisa Henderson, Richard Kelsey, Lara Wilson, Phil Chambers, Debra Taylor, Stan Tyms
  • Patent number: 7582624
    Abstract: Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV.
    Type: Grant
    Filed: September 22, 2003
    Date of Patent: September 1, 2009
    Assignee: Arrow Therapeutics Limited
    Inventors: Malcolm Carter, Philip Chambers, Verity Dowdell, Elisa Ann Henderson, Richard David Kelsey, Debra Taylor, Stanley Tyms, Lara Wilson
  • Publication number: 20080139536
    Abstract: Use of a compound which is (a) a benzodiazepine derivative of the formula (I) or an N-oxide thereof or (b) a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating or preventing an RSV infection wherein: —R1 represents C1-6 alkyl, aryl or heteroaryl; —R2 represents hydrogen or C1-6 alkyl; each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6alkyl)amino, vitro, cyano, —CO2R?, —CONR?R?, —NH—CO—R?, —S(O)R?, —S(O)2R?, —NH—S(O)2R?, —S(O)NR?R? or —S(O)2NR?R?, wherein each R? and R? is the same or different and represents hydrogen or C1-6 alkyl; n is from O to 3; R4 represents hydrogen or C1-6 alkyl; X represents —CO—, —CO—NR?—, —S(O)— or —S(O)2—, wherein R? is hydrogen or a C1-C6 alkyl group; and R5 represents a heteroaryl or heterocyclyl group which is substituted by a C1C6 hydroxyalkyl group or a —(C1-C4 alkyl)-X1—(C1-C4 alkyl)-X2—(C1-C4 alkyl} group
    Type: Application
    Filed: March 18, 2005
    Publication date: June 12, 2008
    Applicant: Novartis Pharmaceuticals Corporation
    Inventors: Verity Dowdell, Richard Kelsey, Malcolm Carter, Dagmar Alber, Elisa Henderson
  • Publication number: 20070293482
    Abstract: A process for producing a compound which is a benzodiazepine derivative of formula: (I) wherein: represents or R1 represents C1-6 alkyl, aryl or heteroaryl; each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, —CO2R?, —CONR?R?, —NH—CO—R?, —S(O)R?, —S(O)2R?, —NH—S(O)2R?, —S(O)NR?R? or —S(O)2NR?R?, wherein each R? and R? is the same or different and represents hydrogen or C1-6 alkyl; n is from 0 to 3; X represents —NH—, —N(C1-C6alkyl)-, —CO—, —CO—NR?—, —S(O)— or —S(O)2—, wherein R? is hydrogen or a C1-C6 alkyl group; and R4 represents hydrogen; or —CO—R4? or —CO—NH—R4 ?, wherein R4 ? is a C1-C6 alkyl, C1-C6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group, which group is substituted by a C1-C6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group or a —(C1-C4 alkyl)-X1—(C1-C4 alkyl)-X2—(C1-C4 alkyl) group, wherein X1 represents —
    Type: Application
    Filed: March 21, 2005
    Publication date: December 20, 2007
    Applicant: Novartis Pharmaceuticals Corporation
    Inventors: Verity Dowdell, Richard Kelsey, Malcolm Carter, Elisa Henderson
  • Publication number: 20070238875
    Abstract: A process for the preparation of a compound of formula (I) comprising the steps: (a) reacting a compound of formula (II) wherein L and L? are suitable leaving groups, with a compound of formula (III) UNH2??(III) to prepare a compound of formula (IV) and subsequently (b) substituting the group R1 by replacement of the leaving group L?.
    Type: Application
    Filed: May 23, 2007
    Publication date: October 11, 2007
    Inventors: Malcolm CARTER, George Cockerill, Stephen Guntrip, Karen Lackey, Kathryn Smith
  • Publication number: 20070185096
    Abstract: A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.
    Type: Application
    Filed: March 18, 2005
    Publication date: August 9, 2007
    Applicant: Novartis Pharmaceuticals Corporation
    Inventors: Kenneth Powell, Richard Kelsey, Malcolm Carter, Verity Dowdell, Dagmar Alber, Elisa Henderson
  • Publication number: 20070142403
    Abstract: A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.
    Type: Application
    Filed: March 18, 2005
    Publication date: June 21, 2007
    Applicant: Novartis Pharmaceuticala Corporation
    Inventors: Kenneth Powell, Richard Kelsey, Malcolm Carter, Dagmar Alber, Lara Wilson, Elisa Henderson, Phil Chambers, Debra Taylor, Stan Tyms, Verity Dowdell
  • Patent number: 7161902
    Abstract: Congestion control in a communications network, e.g. an Internet Protocol (IP) network, is effected by controlling the egress rate of traffic from the output buffer of the system routers or switches. The traffic egressing from an output buffer is sampled at sequential intervals to determine a bit rate at each interval. An autocorrelation function is calculated from these samples and is used to provide an estimated statistical measure or parameter indicative of congestion and related to a long range dependence of the traffic. A calculation is then made as to whether an increase or a decrease in the buffer output rate would result in a decrease in the congestion parameter, and the buffer output rate is adjusted accordingly.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: January 9, 2007
    Assignee: Nortel Networks Limited
    Inventors: Malcolm Carter, David Ireland, Kevin Warbrick, Jon Weil, Peter Hamer, Richard Clegg, Arthur Clune
  • Publication number: 20060040923
    Abstract: Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV.
    Type: Application
    Filed: September 22, 2003
    Publication date: February 23, 2006
    Inventors: Malcolm Carter, Elisa Henderson, Richard Kelsey, Lara Wilson, Phil Chambers, Debra Taylor, Stan Tyms
  • Publication number: 20050282845
    Abstract: Methods for the treatment of pain, fever, inflammation of a variety of conditions and diseases.
    Type: Application
    Filed: June 23, 2005
    Publication date: December 22, 2005
    Inventors: Malcolm Carter, Alan Naylor, Martin Pass, Jeremy Payne, Neil Pegg
  • Publication number: 20050130996
    Abstract: A process for the preparation of a compound of formula (I) comprising the steps: (a) reacting a compound of formula (II) wherein L and L? are suitable leaving groups, with a compound of formula (III) UNH2??(III) to prepare a compound of formula (IV) and subsequently (b) substituting the group R1 by replacement of the leaving group L?.
    Type: Application
    Filed: February 3, 2005
    Publication date: June 16, 2005
    Inventors: Malcolm Carter, George Cockerill, Stephen Guntrip, Karen Lackey, Kathryn Smith
  • Publication number: 20040102466
    Abstract: A compound of formula (I) and pharmaceutically acceptable derivatives thereof, in which R1 is H or C1-4alkyl; R2 is R3 is C1-6alkyl or NH2. Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases.
    Type: Application
    Filed: June 25, 2003
    Publication date: May 27, 2004
    Inventors: Malcolm Carter, Alan Naylor, Martin Pass, Jeremy Payne, Neil Pegg
  • Publication number: 20030035374
    Abstract: Congestion control in a communications network, e.g. an Internet Protocol (IP) network, is effected by controlling the egress rate of traffic from the output buffer of the system routers or switches. The traffic egressing from an output buffer is sampled at sequential intervals to determine a bit rate at each interval. An autocorrelation function is calculated from these samples and is used to provide an estimated statistical measure or parameter indicative of congestion and related to a long range dependence of the traffic. A calculation is then made as to whether an increase or a decrease in the buffer output rate would result in a decrease in the congestion parameter, and the buffer output rate is adjusted accordingly.
    Type: Application
    Filed: May 28, 2002
    Publication date: February 20, 2003
    Inventors: Malcolm Carter, David Ireland, Kevin Warbrick, Jon Weil, Peter Hamer, Richard Clegg, Arthur Clune
  • Patent number: 5786473
    Abstract: A process for the preparation of the compound of formula (I) ##STR1## or a salt thereof which comprises reducing the compound of formula (II) ##STR2## or a salt thereof. The novel intermediate of formula (II) and processes for preparing it are also described.
    Type: Grant
    Filed: March 19, 1997
    Date of Patent: July 28, 1998
    Assignee: Glaxo Group Limited
    Inventors: Philip Blatcher, Malcolm Carter, Roy Hornby, Martin Richard Owen
  • Patent number: 5659040
    Abstract: A process for the preparation of the compound of formula (I) ##STR1## or a salt thereof which comprises reducing the compound of formula (II) ##STR2## or a salt thereof. The novel intermediate of formula (II) and processes for preparing it are also described.
    Type: Grant
    Filed: February 29, 1996
    Date of Patent: August 19, 1997
    Assignee: Glaxo Group Limited
    Inventors: Philip Blatcher, Malcolm Carter, Roy Hornby, Martin Richard Owen
  • Patent number: 5510350
    Abstract: The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt or solvate thereof wherein R.sup.1 represents a hydrogen atom or a halogen atom or a group selected from C.sub.1-6 alkyl and C.sub.1-6 alkoxy;R.sup.2 represents a phenyl group substituted by a group selected from ##STR2## and optionally further substituted by one or two substituents selected from halogen atoms, C.sub.1-6 alkoxy, hydroxy, and C.sub.1-6 alkyl;R.sup.3 represents the group ##STR3## R.sup.4 and R.sup.5, which may be the same or different, each independently represent a hydrogen atom or a halogen atom or a group selected from hydroxy, C.sub.1-6 alkoxy and C.sub.1-6 alkyl;R.sup.6 represents a hydrogen atom or a group selected from --NR.sup.9 R.sup.10 and a C.sub.1-6 alkyl group optionally substituted by one or two substituents selected from C.sub.1-6 alkoxy, hydroxy, C.sub.1-6 acyloxy and --SO.sub.2 R.sup.11 ;R.sup.7, R.sup.8 and R.sup.
    Type: Grant
    Filed: May 3, 1994
    Date of Patent: April 23, 1996
    Assignee: Glaxo Group Limited
    Inventors: Alexander W. Oxford, William L. Mitchell, John Bradshaw, John W. Clitherow, Malcolm Carter
  • Patent number: 5340810
    Abstract: The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt or solvate thereof wherein R.sup.1 represents a hydrogen atom or a halogen atom or a group selected from C.sub.1-6 alkyl and C.sub.1-6 alkoxy;R.sup.2 represents a phenyl group substituted by a group selected from ##STR2## and optionally further substituted by one or two substituents selected from halogen atoms, C.sub.1-6 alkoxy, hydroxy, and C.sub.1-6 alkyl;R.sup.3 represents the group ##STR3## R.sup.4 and R.sup.5, which may be the same or different each independently represent a hydrogen atom or a halogen atom or a group selected from hydroxy, C.sub.1-6 alkoxy and C.sub.1-6 alkyl;R.sup.6 represents a hydrogen atom or a group selected from --NR.sup.9 R.sup.10 and a C.sub.1-6 alkyl group optionally substituted by one or two substituents selected from C.sub.1-6 alkoxy, hydroxy, C.sub.1-6 acyloxy and --SO.sub.2 R.sup.11 ;R.sup.7, R.sup.8 and R.sup.
    Type: Grant
    Filed: September 17, 1992
    Date of Patent: August 23, 1994
    Assignee: Glaxo Group Limited
    Inventors: John W. Clitherow, Malcolm Carter